All In Biotech

Drug Trial Radar · NCT07937254

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of JAR-2203 in Healthy Participants With Elevated Plasma Lipoprotein(a)

A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Administration of JAR-2203 in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

44

Planned (sponsor's estimate)

Start

Oct 19, 2026

Primary completion

Jul 30, 2027

Study completion Nov 30, 2027

Sponsor

Sponsor type
Industry
First posted
Nov 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This first-in-human Phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and effects on Lp(a) of single ascending doses of JAR-2203 in healthy adults with elevated Lp(a).

Conditions

  • Lipid Metabolism Disorders
  • Healthy Volunteers - Male and Female
  • Hyperlipoproteinemia(a)

Interventions

  • JAR-2203Drug

    JAR-2203 solution for injection given as a single subcutaneous injection; planned dose levels are 7.5, 30, 75, 150, 225, and 300 mg.

  • PlaceboDrug

    Placebo for injection given as a single subcutaneous injection at a volume matched to the active treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)Time frame: From first dose until the end of the study (through Day 169).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.